VYGR Voyager Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why VYGR matters now
Voyager Therapeutics, Inc. (VYGR) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.44 with -6.52% on the session and $207.8M in market capitalization; recent performance reads 1-month +6.90% and YTD -5.34%.
The latest financial table shown here is Q1 2026, with revenue of $2.6M, net income of $-27.9M, and EPS of $-0.47. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -57.8%.
The latest indexable market news headline is "Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money" from 24/7 Wall Street.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.00; recent insider activity includes PIERCE GLENN filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.27
P/S
6.16
EV/EBITDA
-1.92
DCF Value
$-4.46
FCF Yield
-57.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-86.7%
Operating Margin
-349.2%
Net Margin
-319.6%
ROE
-56.0%
ROA
-53.2%
ROIC
-60.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.6M | $-27.9M | $-0.47 |
| Q4 2025 | $15.3M | $-27.4M | $-0.47 |
| FY 2025 | $40.4M | $-119.7M | $-2.04 |
| Q3 2025 | $13.4M | $-27.9M | $-0.47 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$14.40
Target (Median)
$18.00
Target Range
$8.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.25
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.